Azenta Inc (Azenta), formerly Brooks Automation Inc, provides sample exploration and management solutions for the life sciences industry.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Azenta’s research and development efforts are centered on advancing its product offerings, improving functionality, and enhancing integration, reliability, and performance across its solutions. A key focus of Azenta’s R&D is the development of automated biological sample storage solutions for ultra-low temperature environments. The company offers a complete range of automated storage systems, from ambient temperatures down to -190°C, with the capability for controlled storage down to -80°C. These systems are designed to provide enhanced data management, sample security, and the highest throughput for sample retrieval, making them ideal for vaccines, biologics, and other temperature-sensitive materials. Azenta also drives innovation in its genomic services, advancing research in gene sequencing, synthesis, editing, and related technologies. The company has developed a comprehensive global portfolio to address the unique needs of key markets such as cell and gene therapy (CGT), antibody development, and biomarker discovery. Its R&D investments are also focused on expanding solutions in multiomics and proteomics, enabling more efficient drug discovery and development. Azenta’s 14 genomic service laboratories across the US, China, the UK, Japan, and Germany further strengthen its ability to provide advanced solutions. In FY2025, the company invested US$30.3 million in R&D, which represented 5.1% of its revenue and decreased by 3.5% YoY.